Quality of Life in Younger Leukemia and Lymphoma Survivors
This study has been completed.
Sponsor:
Case Comprehensive Cancer Center
Collaborator:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00956475
First received: August 8, 2009
Last updated: August 23, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This phase I trial is studying quality of life in younger leukemia and lymphoma survivors.
| Condition | Intervention | Phase |
|---|---|---|
|
Anxiety Disorder Cancer Survivor Fatigue Leukemia Long-term Effects Secondary to Cancer Therapy in Adults Lymphoma Lymphoproliferative Disorder Pain Psychosocial Effects of Cancer and Its Treatment Small Intestine Cancer |
Behavioral: telephone-based intervention Other: questionnaire administration Procedure: assessment of therapy complications Procedure: fatigue assessment and management Procedure: psychosocial assessment and care Procedure: quality-of-life assessment |
Phase 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Quality of Life in Young Adult Survivors of Hematologic Malignancies |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial acute myeloid leukemia with mutated CEBPA
mycosis fungoides
Sézary syndrome
MedlinePlus related topics:
Acute Myeloid Leukemia
Anxiety
Cancer
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Fatigue
Fungal Infections
Hodgkin Disease
Intestinal Cancer
Leukemia
Lymphoma
U.S. FDA Resources
Further study details as provided by Case Comprehensive Cancer Center:
Primary Outcome Measures:
- Quality of life [ Time Frame: 1-10 years after treatment ] [ Designated as safety issue: No ]
- Most common areas of concern [ Time Frame: 1-10 years after treatment ] [ Designated as safety issue: No ]
| Enrollment: | 48 |
| Study Start Date: | October 2008 |
| Study Completion Date: | August 2011 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Behavioral: telephone-based intervention
Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
Other: questionnaire administration
Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
Procedure: assessment of therapy complications
questionnaire via telephone
Procedure: fatigue assessment and management
questionnaire via telephone
Procedure: psychosocial assessment and care
questionnaire via telephone
Procedure: quality-of-life assessment
questionnaire via telephone
OBJECTIVES:
- To collect preliminary data to determine the extent to which there is impairment in quality of life of young adult survivors of hematologic malignancies.
- To identify the most common areas of concern in these survivors.
- To explore patterns of quality-of-life impairment associated with age, gender, and type of treatment (transplant vs non-transplant) in these survivors.
OUTLINE: Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
Eligibility| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Records from the practice of the study investigators will be reviewed to identify patients.
Criteria
DISEASE CHARACTERISTICS:
- Survivors of leukemia (i.e., acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or chronic lymphocytic leukemia) or lymphoma (i.e., non-Hodgkin lymphoma or Hodgkin lymphoma) who have received any cytotoxic or radiation therapy
- Received treatment for leukemia or lymphoma 1-10 years ago
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00956475
Locations
| United States, Ohio | |
| Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | |
| Cleveland, Ohio, United States, 44106-5065 | |
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
| Principal Investigator: | Regan Demshar, RN | Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Case Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00956475 History of Changes |
| Other Study ID Numbers: | CASE11Z08, P30CA043703, CASE11Z08, CASE 11Z08-CC607 |
| Study First Received: | August 8, 2009 |
| Last Updated: | August 23, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Case Comprehensive Cancer Center:
|
anxiety disorder long-term effects secondary to cancer therapy in adults fatigue pain psychosocial effects of cancer and its treatment cancer survivor accelerated phase chronic myelogenous leukemia acute undifferentiated leukemia adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) |
atypical chronic myeloid leukemia blastic phase chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia mast cell leukemia meningeal chronic myelogenous leukemia progressive hairy cell leukemia, initial treatment prolymphocytic leukemia recurrent adult acute lymphoblastic leukemia recurrent adult acute myeloid leukemia refractory chronic lymphocytic leukemia refractory hairy cell leukemia relapsing chronic myelogenous leukemia secondary acute myeloid leukemia stage I chronic lymphocytic leukemia |
Additional relevant MeSH terms:
|
Anxiety Disorders Fatigue Leukemia Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma, Large-Cell, Immunoblastic Duodenal Neoplasms Ileal Neoplasms Jejunal Neoplasms Intestinal Neoplasms Mental Disorders Signs and Symptoms Neoplasms by Histologic Type |
Neoplasms Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Duodenal Diseases Intestinal Diseases Ileal Diseases Jejunal Diseases |
ClinicalTrials.gov processed this record on May 22, 2013